XLOXilio Therapeutics, Inc.

$29M

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$20M

Net Income

-$20M

EPS (Diluted)

$-0.98

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$17M

Free Cash Flow

-$18M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$222M

Total Liabilities

$36M

Stockholders' Equity

$185M

Cash & Equivalents

$198M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$20M	-$21M	+5.0%
Net Income	-$20M	-$21M	+5.2%

XLO Q4 2021 Earnings — Xilio Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena